Intraocular Sustained Release of EPO-R76E Mitigates Glaucoma Pathogenesis by Activating the NRF2/ARE Pathway

• Váldodahkkit: Sarah Naguib (Dahkki), Carlisle R. DeJulius (Dahkki), Jon R. Backstrom (Dahkki), Ameer A. Haider (Dahkki), John M. Ang (Dahkki), Andrew M. Boal (Dahkki), David J. Calkins (Dahkki), Craig L. Duvall (Dahkki), Tonia S. Rex (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: MDPI AG, 2023-02-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Erythropoietin (EPO) is neuroprotective in multiple models of neurodegenerative diseases, including glaucoma. EPO-R76E retains the neuroprotective effects of EPO but diminishes the effects on hematocrit. Treatment with EPO-R76E in a glaucoma model increases expression of antioxidant proteins and is...